Stock Events

Stock Events

Orphazyme A/S 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15SepExpected
Q1 2023
Next
-540.99
-540.65
-540.32
-539.99
Expected EPS
N/A
Actual EPS
N/A

Financials

-278.42%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
41,371.74Revenue
-115,186.31Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1TB.MU. It's not an investment recommendation.
Apple
3
AAPL
Realty Income
3
O
Coca-Cola
3
KO
AT&T
3
T

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap29.4B
Biogen is a biotech firm with a strong focus on neurodegenerative diseases, similar to Orphazyme's focus on rare diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals is involved in treating cystic fibrosis, a rare disease, showing its capability and interest in the rare disease market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for rare genetic diseases, aligning with Orphazyme's rare disease treatment goals.
Sarepta Therapeutics
SRPT
Mkt Cap2B
Sarepta Therapeutics specializes in the treatment of rare genetic diseases, particularly in the area of Duchenne muscular dystrophy.
Ionis Pharmaceuticals
IONS
Mkt Cap13.52B
Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, working on treatments for rare diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing in the same rare disease space as Orphazyme.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is involved in gene editing, a technology that has the potential to treat the genetic roots of many rare diseases.
Novo Nordisk
NVO
Mkt Cap218.94B
Novo Nordisk, while known for diabetes care, is expanding into treatments for rare blood disorders, showing its growing interest in the rare disease sector.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the rare disease market space.

About

Initially operating as Orphazyme A/S, the company adopted its current name, Strategic Partners A/S, in October 2024. Established in 2009, this Danish entity is headquartered in Herlev. Historically, its primary focus was on biotechnology; however, it presently conducts no significant business operations.
Show more...
CEO
ISIN
DK0060910917

Listings

CO
DK
STRAP.CO
STU
DE
1TB0.STU
MU
DE
1TB.MU
MU
DE
1TBD.MU

0 Comments

Share your thoughts

FAQ

What is Orphazyme A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Orphazyme A/S stocks are traded under the ticker 1TB.MU.
When is the next Orphazyme A/S earnings date?▼
Orphazyme A/S is going to release the next earnings report on September 15, 2026.
What is Orphazyme A/S revenue for the last year?▼
Orphazyme A/S revenue for the last year amounts to 41,371.74 EUR.
What is Orphazyme A/S net income for the last year?▼
1TB.MU net income for the last year is -115,186.31 EUR.
In which sector is Orphazyme A/S located?▼
Orphazyme A/S operates in the Other sector.
When did Orphazyme A/S complete a stock split?▼
Orphazyme A/S has not had any recent stock splits.